New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
05:55 EDTKO, KO, KO, KO, WM, WM, WM, WM, NHI, NHI, NHI, NHI, NCLH, NCLH, NCLH, NCLH, MDT, MDT, MDT, MDT, HTA, HTA, HTA, HTA, DSX, DSX, DSX, DSX, CMLS, CMLS, CMLS, CMLS, CHH, CHH, CHH, CHH, WWW, WWW, WWW, WWWNotable companies reporting before Tuesday's open
Notable companies reporting before Tuesday's open, with earnings consensus, include Coca-Cola (KO), consensus 46c; Choice Hotels (CHH) consensus 46c; Cumulus Media (CMLS), consensus 8c; Diana Shipping (DSX), consensus (6c); Healthcare Trust of America (HTA), consensus 17c; Medtronic (MDT), consensus 91c; Norwegian Cruise Line (NCLH), consensus 18c; National Health Investors (NHI), consensus 18c; Waste Management (WM), consensus 60c; Wolverine World Wide (WWW), consensus 20c. The Fly notes that in observation of the Presidents' Day holiday, U.S. markets will be closed on Monday, February 17.
News For KO;CHH;CMLS;DSX;HTA;MDT;NCLH;NHI;WM;WWW From The Last 14 Days
Check below for free stories on KO;CHH;CMLS;DSX;HTA;MDT;NCLH;NHI;WM;WWW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 26, 2014
05:54 EDTMDTMedtronic acquires Sapiens SBS for $200M
Subscribe for More Information
August 25, 2014
10:03 EDTMDTMedtronic announces FDA approval of Viva CRT-P for heart failure or AV block
Subscribe for More Information
August 20, 2014
09:02 EDTDSXDiana Shipping announces delivery of Capesize vessel m/v G. P. Zafirakis
Subscribe for More Information
08:47 EDTMDTMedtronic valuation attractive, says Morgan Stanley
Morgan Stanley said Medtronic's (MDT) valuation is attractive given pipeline execution, margin growth and shareholder returns, and expectations for the Covidien (COV) deal to go through. Shares are Overweight rated
07:18 EDTMDTMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
16:17 EDTHTAHealthcare Trust appoints Robert Milligan as CFO
Subscribe for More Information
10:13 EDTWWWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTMDTMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:39 EDTWWWWolverine World Wide upgraded at KeyBanc
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
05:29 EDTWWWWolverine World Wide upgraded to Buy from Hold at KeyBanc
Subscribe for More Information
August 18, 2014
15:26 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:49 EDTMDTMedtronic technical comments before earnings
Subscribe for More Information
13:59 EDTMDTMedtronic August weekly 63.5 straddle priced for 2% move into Q1
Subscribe for More Information
13:12 EDTKOAnalysts mixed on Monster Beverage following Coke deal
Analysts had mixed outlooks on energy drink maker Monster Beverage (MNST) in notes to investors earlier today. The analyst comments come after last Thursday night’s announcement that Monster had formed a strategic partnership with Coca-Cola, which included Coca-Cola taking a 16.7% stake in the energy drink maker. BEARISH TAKE: Jefferies analyst Kevin Grundy downgraded Monster Beverage to Hold from Buy, saying that the stock's valuation "looks full" following its rally on Friday. The potential for a strategic deal is no longer a positive catalyst for Monster's stock, as that catalyst largely played out Friday, Grundy believes. Although Coca-Cola is likely to increase its stake in Monster, it will likely take years to do so, the analyst forecast. Additionally, the growth of the global energy drink space has been slowing in recent months, creating risk for Monster, the analyst believes. However, Grundy did raise his price target on the shares to $95 from $80. BULLISH TAKE: The deal is "a big win" for both Monster and Coca-Cola, but Monster will benefit more, analysts at Wells Fargo contended. The deal should significantly increase Monster's opportunity in international markets, according to the firm. Moreover, Wells believes that the market has historically undervalued Monster's international potential, and it estimates that the company's international business is worth about $65 per share. The firm raised its price target range on the stock to $104-$106 from $79-$81 and kept an Outperform rating on the shares. Like Wells Fargo, Credit Suisse expects the deal to accelerate the growth of Monster's international business. Additionally, the firm thinks that Monster could return a significant percentage of the $2.1B it received from Coca-Cola to shareholders, either through share repurchases or a one-time dividend. Credit Suisse increased its price target on Coca-Cola to $98 from $82 and kept an Outperform rating on the shares. PRICE ACTION: In early afternoon trading, Monster dropped 4% to $89.50. On Thursday the stock closed at $71.65.
07:41 EDTKOMonster Beverage price target raised to $104-$106 from $79-$81 at Wells Fargo
Subscribe for More Information
06:24 EDTMDTOptions expected to be active
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use